<DOC>
	<DOCNO>NCT00175292</DOCNO>
	<brief_summary>This randomized placebo-controlled double-blind , multi-centre trial determine efficacy probiotic VSL # 3 prevention Crohn 's disease development follow surgical resection re-anastomosis . A total 120 patient randomly assign 1:1 ratio receive VSL # 3 placebo 90 day . Patients respond study treatment , define absence severe endoscopic recurrence day 90 , offer open-label VSL # 3 additional 9 month .</brief_summary>
	<brief_title>A Randomized Controlled Trial VSL # 3 Prevention Endoscopic Recurrence Following Surgery Crohn 's Disease .</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>1 . Subjects 16 year age old 2 . Diagnosis Crohn 's disease 3 . Resection ileocolonic Crohn 's disease small bowel colonic anastomosis within 30 day randomization 4 . Able provide inform write consent 5 . Women childbearing potential negative serum pregnancy test , and/or use effective contraception 1 . Use perioperative steroid taper dos antidiarrheal agent 2 . Treatment TNFantagonist 8 week prior resection 3 . Clinically significant Crohn 's disease elsewhere GI tract 4 . Clinically document short bowel syndrome 5 . Serious disease Crohn 's disease 6 . Impaired liver renal function 7 . History cancer le 2 year diseasefree state 8 . Abnormal Laboratory value 9 . Alcohol drug abuse 10 . Some psychiatric condition 11 . Patients use study medication 12 . Patients unable attend study visit comply study procedure 13 . Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>